Insider Transactions in Q3 2021 at T Scan Therapeutics, Inc. (TCRX)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2021
|
Zoran Zdraveski |
BUY
Open market or private purchase
|
Direct |
4,716
+50.0%
|
$33,012
$7.48 P/Share
|
|
Sep 21
2021
|
Brian M. Silver Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+29.61%
|
$30,000
$6.32 P/Share
|
|
Sep 21
2021
|
Gavin Mac Beath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
57
+0.11%
|
$342
$6.19 P/Share
|
|
Sep 20
2021
|
Gavin Mac Beath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,943
+9.04%
|
$29,658
$6.22 P/Share
|
|
Sep 09
2021
|
Brian M. Silver Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,885
+46.08%
|
$47,080
$8.48 P/Share
|
|
Sep 08
2021
|
David P Southwell Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
11,000
+10.1%
|
$88,000
$8.73 P/Share
|
|
Aug 27
2021
|
William Desmarais Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$22,500
$9.08 P/Share
|
|
Jul 20
2021
|
Timothy J Barberich |
BUY
Conversion of derivative security
|
Direct |
33,259
+50.0%
|
-
|
|
Jul 20
2021
|
Christoph H Westphal > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
133,333
+9.44%
|
$1,999,995
$15.0 P/Share
|
|
Jul 20
2021
|
Christoph H Westphal > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,145,505
+50.0%
|
-
|
|
Jul 20
2021
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1,425,000
+50.0%
|
$21,375,000
$15.0 P/Share
|
|
Jul 20
2021
|
Brian M. Silver Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$15,000
$15.0 P/Share
|